Form 4: Jazz Pharmaceuticals Executive Reports Stock Transactions

Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports acquisition and disposal of ordinary shares.

Summary

• On March 1, 2024, Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reported transactions involving the company's ordinary shares.
• Pearce acquired 5,065 ordinary shares at a price of $0.0.
• Pearce also disposed of 19,396 ordinary shares.
• Following these transactions, Pearce's beneficially owned shares are not specified in this report.
• The reported transactions also include restricted stock units granted under the 2011 Equity Incentive Plan, vesting in equal annual installments over four years starting March 5, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The restricted stock units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock. It's a standard practice for executives at publicly traded companies like Jazz Pharmaceuticals.

Key Dates